AG
SPRY icon

Algert Global’s ARS Pharmaceuticals SPRY Stock Holding History

Algert Global’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,920
Closed -$170K – 1299
2022
Q4 		$170K Hold
19,920
– – 0.01% 1032
2022
Q3 		$105K Buy
+19,920
New +$98.2K 0.01% 1104

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Algert Global's SPRY Position: Q1 2023 in Review

Algert Global sold out of ARS Pharmaceuticals (SPRY) in Q1 2023, closing a stake of 19,920 shares — an estimated $170K sold.

Algert Global first reported a position in SPRY in Q3 2022 and held it in 2 quarters. The position peaked at $170K in Q4 2022. 89 funds tracked by Wall St. Rank hold SPRY as of Q1 2023.

  • Algert Global reported no remaining ARS Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Algert Global sold 19,920 ARS Pharmaceuticals shares in Q1 2023, an estimated $170K.
  • Algert Global first reported a position in ARS Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Algert Global's ARS Pharmaceuticals position peaked at $170K in Q4 2022.
  • 89 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2023.

Based on Algert Global's 13F filing for Q1 2023, filed 12 May 2023.